Pyrocatechol violet as a marker to characterize liposomal membrane permeability using the chelation and the first-order derivative spectrophotometry

2005 ◽  
Vol 37 (2) ◽  
pp. 379-382 ◽  
Author(s):  
Yiguang Jin ◽  
Miao Li ◽  
Xinpu Hou
2002 ◽  
Vol 35 (7) ◽  
pp. 1193-1204 ◽  
Author(s):  
Hassan Y. Aboul-Enein ◽  
Nilgün Günden Göğer ◽  
Alphun Türkalp

2008 ◽  
Vol 91 (5) ◽  
pp. 1075-1082 ◽  
Author(s):  
Dimal A Shah ◽  
Kashyap K Bhatt ◽  
Rajendra S Mehta ◽  
Sunil L Baldania

Abstract Two simple and accurate methods for analysis of nebivolol hydrochloride (NEB) and hydrochlorothiazide (HCTZ) in their combined dosage forms were developed using first-order derivative spectrophotometry and reversed-phase liquid chromatography (LC). NEB and HCTZ in their combined dosage forms (tablets) were quantified using first-derivative responses at 294.6 and 334.6 nm in the spectra of their solutions in methanol. The calibration curves were linear in the concentration range of 840 g/mL for NEB and 1060 g/mL for HCTZ. LC analysis was performed on a Phenomenex Gemini C18 column (250 4.6 mm id, 5 m particle size) in the isocratic mode with 0.05 M potassium dihydrogen phosphateacetonitrilemethanol (30 + 20 + 50, v/v/v; pH 4) mobile phase at a flow rate of 1 mL/min. Detection was made at 220 nm. Both of the drugs and the internal standard (ezetimibe) were well resolved with retention times of 5.1 min for NEB, 2.9 min for HCTZ, and 8.2 min for ezetimibe. The calibration curves were linear in the concentration range of 114 g/mL for NEB and 0.328 g/mL for HCTZ. Both methods were validated and found to be accurate, precise, and specific, and results were compared statistically. Developed methods were successfully applied for the estimation of NEB and HCTZ in their combined dosage forms.


2009 ◽  
Vol 25 (4) ◽  
pp. 487-492 ◽  
Author(s):  
Vitor C. ALMEIDA ◽  
Alexandro M. M. VARGAS ◽  
Juliana C. GARCIA ◽  
Ervim LENZI ◽  
Cláudio C. OLIVEIRA ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
K. Anandakumar ◽  
P. Veerasundari

Paracetamol, ambroxol hydrochloride, levocetirizine dihydrochloride, and phenylephrine hydrochloride are used in combination for the treatment of chronic sinusitis, rhinitis, fever, nasal discharge, sore throat, and wheezing. The present work deals with method development for simultaneous estimation of paracetamol, ambroxol hydrochloride, levocetirizine dihydrochloride, and phenylephrine hydrochloride in tablet formulation by first-order derivative spectrosphotometry. For determination of sampling wavelength, 10 μg/mL of each of paracetamol, ambroxol hydrochloride, levocetirizine dihydrochloride, and phenylephrine hydrochloride was scanned in 200–400 nm ranges and sampling wavelengths were found to be 305.5 nm for paracetamol, 321 nm for ambroxol hydrochloride, 244 nm for levocetirizine dihydrochloride, and 280 nm for phenylephrine hydrochloride in first-order derivative spectrophotometry. In this method, linearity was observed in the ranges of 20–140 μg/mL for paracetamol and 10–70 μg/mL for ambroxol hydrochloride, levocetirizine dihydrochloride, and phenylephrine hydrochloride. The % recovery was within the range between 98 and 102%, and % relative standard deviation for precision and accuracy of the method was found to be less than 2%. The method is validated as per International Conference on Harmonization Guidelines. The method can be successfully applied for the simultaneous analysis of these drugs in pharmaceutical dosage forms.


Sign in / Sign up

Export Citation Format

Share Document